Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

Completed · Not applicable

Conditions studied: HIV Infection

In brief

Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment regimen of these patients may result in an increase in their CD4 counts. As the patient would be continuing their prior regimen, they will likely continue with full control of viral replication.

Key facts

Study ID

NCT02934022

Run by

Southern California Institute for Research and Education

People needed

25

Starts

2012-06-01

Expected to finish

2014-12-01

Last updated by the study team

2016-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 positive.
• Receiving highly active antiretroviral therapy (HAART).
• HIV-1 viral load of < 48 copies for 12 months or more.
• CD4 lymphocyte count that has not gone above 500. -

You may not qualify if…

• Severe hepatic impairment (cirrhosis) or active Hepatitis C with liver transaminases > 5 times normal.
• Severe renal impairment (creatinine clearance < 30 ml/min) or end-stage renal disease (ESRD) who are taking potent CYP3A4 inhibitors or inducers.
• Receiving certain necessary medications that have the potential for serious drug-drug interactions with maraviroc. -

Where it is running

• VA Long Beach Healthcare System — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.